FORE Biotherapeutics today announced that the Company will participate at the following investor conferences:

• Wells Fargo Healthcare Conference. The Company will attend on Wednesday, September 3, and will provide a corporate presentation at 12:45 p.m. – 1:20 p.m. ET.

• Cantor Fitzgerald Global Healthcare Conference. The Company will attend and participate in one-on-one meetings on Thursday, September 4.

Management will host and participate in one-on-one meetings. Please contact Argot Partners to schedule one-on-one meetings with the management team.

About FORE Biotherapeutics

Fore is a registration stage targeted oncology company dedicated to developing innovative treatments that provide better outcomes for patients with the hardest-to-treat cancers. The Company’s lead asset plixorafenib (FORE8394; formerly PLX8394) is a V600 and non-V600 BRAF inhibitor rationally designed with a first-in-class mechanism to address treatment gaps from 1^st and 2^nd generation BRAF inhibitors. Plixorafenib has demonstrated single-agent efficacy signals across a variety of tumor types with a manageable safety profile in a Phase 1/2a clinical trial of over 100 patients and is currently enrolling patients in FORTE, a global registrational basket trial to support three distinct indications. For more information, please visit www.fore.bio or follow us on X and LinkedIn.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250827877608/en/